MGN1703: Additional Phase III data

Additional data from the double-blind, international Phase II IMPACT trial in 59 patients with mCRC showed that twice-weekly 60 mg MGN1703 as maintenance therapy led to a median OS of 22.6 vs. 15.1 mo...